Management of Liver Tumors during the COVID-19 Pandemic: The Added Value of Selective Internal Radiation Therapy (SIRT).
COVID-19
cholangiocarcinoma
hepatocellular carcinoma
holmium
liver cancer
metastases
pandemic
radioembolization
yttrium
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
22 Sep 2021
22 Sep 2021
Historique:
received:
12
08
2021
revised:
14
09
2021
accepted:
20
09
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
14
10
2021
Statut:
epublish
Résumé
In the context of the coronavirus disease 2019 (COVID-19) pandemic, liver-directed therapies (LDTs) may offer minimally invasive integrative tools for tumor control. Among them, selective internal radiation therapy (SIRT) represents a safe, flexible and effective treatment. Purpose of this study is to present our experience with SIRT during the first wave of COVID-19 pandemic and provide an overview of the indications and challenges of SIRT in this scenario. We retrospectively analyzed the number of patients evaluated by Multidisciplinary Liver Tumor Board (MLTB) and who were undergoing LDTs between March and July 2020 and compared it with 2019. For patients treated with SIRT, clinical data, treatment details and the best radiological response were collected. Compared to 2019, we observed a 27.5% reduction in the number of patients referred to MLTB and a 28.3% decrease in percutaneous ablations; transarterial chemoembolizations were stable, while SIRT increased by 64%. The majority of SIRT patients (75%) had primary tumors, mostly HCC. The best objective response and disease control rates were 56.7% and 72.2%, respectively. The first wave of the COVID-19 pandemic was characterized by an increased demand for SIRT, which represents a safe, flexible and effective treatment, whose manageability will further improve by simplifying the treatment workflow, developing user-friendly and reliable tools for personalized dosimetry and improving interdisciplinary communication.
Sections du résumé
BACKGROUND
BACKGROUND
In the context of the coronavirus disease 2019 (COVID-19) pandemic, liver-directed therapies (LDTs) may offer minimally invasive integrative tools for tumor control. Among them, selective internal radiation therapy (SIRT) represents a safe, flexible and effective treatment. Purpose of this study is to present our experience with SIRT during the first wave of COVID-19 pandemic and provide an overview of the indications and challenges of SIRT in this scenario.
METHODS
METHODS
We retrospectively analyzed the number of patients evaluated by Multidisciplinary Liver Tumor Board (MLTB) and who were undergoing LDTs between March and July 2020 and compared it with 2019. For patients treated with SIRT, clinical data, treatment details and the best radiological response were collected.
RESULTS
RESULTS
Compared to 2019, we observed a 27.5% reduction in the number of patients referred to MLTB and a 28.3% decrease in percutaneous ablations; transarterial chemoembolizations were stable, while SIRT increased by 64%. The majority of SIRT patients (75%) had primary tumors, mostly HCC. The best objective response and disease control rates were 56.7% and 72.2%, respectively.
CONCLUSION
CONCLUSIONS
The first wave of the COVID-19 pandemic was characterized by an increased demand for SIRT, which represents a safe, flexible and effective treatment, whose manageability will further improve by simplifying the treatment workflow, developing user-friendly and reliable tools for personalized dosimetry and improving interdisciplinary communication.
Identifiants
pubmed: 34640332
pii: jcm10194315
doi: 10.3390/jcm10194315
pmc: PMC8509348
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Hepatol. 2014 Jun;60(6):1268-89
pubmed: 24681130
J Vasc Interv Radiol. 2017 Jun;28(6):777-785.e1
pubmed: 28365172
J Hepatol. 2018 Apr;68(4):724-732
pubmed: 29331342
Eur J Nucl Med Mol Imaging. 2021 Jun 19;:
pubmed: 34148118
Radiology. 2020 Sep;296(3):673-684
pubmed: 32602828
J Vasc Interv Radiol. 2019 Mar;30(3):414-420
pubmed: 30819485
J Gastrointest Surg. 2021 Aug 3;:
pubmed: 34345997
Cardiovasc Intervent Radiol. 2021 Jan;44(1):21-35
pubmed: 32959085
Onco Targets Ther. 2018 Oct 25;11:7315-7321
pubmed: 30498358
J Hepatol. 2013 Oct;59(4):753-61
pubmed: 23707371
Lancet Gastroenterol Hepatol. 2021 Jan;6(1):17-29
pubmed: 33166497
J Hepatol. 2019 Dec;71(6):1164-1174
pubmed: 31421157
JAMA Oncol. 2020 Jan 1;6(1):51-59
pubmed: 31670746
Hepatobiliary Surg Nutr. 2018 Dec;7(6):487-489
pubmed: 30652096
Lancet Oncol. 2017 Dec;18(12):1624-1636
pubmed: 29107679
Cardiovasc Intervent Radiol. 2021 May;44(5):728-738
pubmed: 33709272
Hepatology. 2021 Jan;73 Suppl 1:158-191
pubmed: 32430997
J Clin Oncol. 2018 Jul 1;36(19):1913-1921
pubmed: 29498924
JCO Glob Oncol. 2020 Sep;6:1428-1438
pubmed: 32986516
J Vasc Interv Radiol. 2020 Sep;31(9):1442-1448
pubmed: 32800662
Clin Transl Imaging. 2020 Sep 24;:1-3
pubmed: 32989416
World J Gastrointest Oncol. 2021 May 15;13(5):440-452
pubmed: 34040704
Hepatology. 2021 Mar 19;:
pubmed: 33739462
Cancer Treat Rev. 2021 Sep;99:102258
pubmed: 34252720
J Nucl Med. 2021 Mar 19;:
pubmed: 33741643
Radiol Med. 2020 Oct;125(10):971-980
pubmed: 32270335
J Nucl Med. 2020 Dec;61(12):1736-1742
pubmed: 32358087
J Gastrointest Oncol. 2020 Apr;11(2):443-460
pubmed: 32399284
J Vasc Interv Radiol. 2020 Dec;31(12):2028-2032
pubmed: 33121865
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Cardiovasc Intervent Radiol. 2020 Sep;43(9):1305-1314
pubmed: 32642986
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1570-1584
pubmed: 33433699
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Lancet Oncol. 2020 Apr;21(4):561-570
pubmed: 32112737
Lancet Oncol. 2020 May;21(5):629-630
pubmed: 32247319
J Vasc Interv Radiol. 2018 Jul;29(7):936-942
pubmed: 29753675
Hepatology. 2021 Mar;73(3):998-1010
pubmed: 32416631
Cancers (Basel). 2020 Jun 12;12(6):
pubmed: 32545572
Ann Surg. 2020 Aug;272(2):e112-e117
pubmed: 32675512
Lancet Oncol. 2017 Sep;18(9):1159-1171
pubmed: 28781171
J Hepatol. 2020 Jun;72(6):1151-1158
pubmed: 32145255
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
J Hepatol. 2020 Jun;72(6):1046-1048
pubmed: 32276729
Ann Surg Oncol. 2020 Jun;27(6):1717-1720
pubmed: 32270420
Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1695-1704
pubmed: 31098749
J Nucl Med. 2020 Sep;61(9):1278-1283
pubmed: 32709733